To further substantiate that AMPK primarily regulates cardiac hypertrophy by modulating O-GlcNAcylation, a group of WT mice were co-treated with 1,2-dideoxy-2′-propyl-alpha-d-glucopyranoso-[2,1-D]-Delta 2′-thiazoline (NButGT), an OGA inhibitor compatible with chronic utilization in vivo. The gene discussed is PRKAA2; the disease is cardiac hypertrophy.